Literature DB >> 17613710

Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals.

Ned Sacktor1, Richard Skolasky, Ola A Selnes, Michael Watters, Pamela Poff, Bruce Shiramizu, Cecilia Shikuma, Victor Valcour.   

Abstract

Human immunodeficiency virus (HIV) dementia remains as an important cause of neurological morbidity among HIV-seropositive (HIV+) individuals. Differences in the neuropsychological profiles between older and younger HIV+ individuals have not been examined extensively. The objective of this study was to examine the neuropsychological test performance between old and young HIV+ individuals (a) with and without cognitive impairment (total cohort) and (b) with dementia. One hundred thirty-three older (age >or= 50 years) HIV+ individuals and 121 younger (age 20 to 39 years) HIV+ individuals were evaluated with a standardized neuropsychological test battery. Differences between age groups in the mean z score for each neuropsychological test were determined. The older HIV+ (total) cohort had greater impairment in tests of verbal memory (P = .006), visual memory (P < .002), verbal fluency (P = .001), and psychomotor speed (P < .001) compared to the young HIV+ (total) cohort. After adjusting for differences in education, older HIV+ patients with dementia (n = 31) had a greater deficit in the Trail Making test Part B (P = 0.02) compared to younger HIV+ patients with dementia (n = 15). Age was associated with lower performance in tests of memory, executive functioning, and motor performance in older HIV+ individuals with and without cognitive impairment (total cohort), compared to younger HIV+ individuals. Among HIV+ patients with dementia, age may be associated with greater impairment in a test of executive functioning. These differences could be a result of advanced age itself or age-associated comorbidities such as coexisting cerebrovascular or neurodegenerative disease.

Entities:  

Mesh:

Year:  2007        PMID: 17613710     DOI: 10.1080/13550280701258423

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  19 in total

1.  Further crossvalidation of regression-based neuropsychological norms with an update for the Boston Naming Test.

Authors:  R K Heaton; N Avitable; I Grant; C G Matthews
Journal:  J Clin Exp Neuropsychol       Date:  1999-08       Impact factor: 2.475

2.  Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders.

Authors: 
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

3.  The relationship between age and cognitive function in HIV-infected men.

Authors:  Emily C Kissel; Nicole D Pukay-Martin; Robert A Bornstein
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2005       Impact factor: 2.198

4.  Retrograde amnesia in dementia: comparison of HIV-associated dementia, Alzheimer's disease, and Huntington's disease.

Authors:  Joseph R Sadek; Shannon A Johnson; Desirée A White; David P Salmon; Kirsten I Taylor; Jody H Delapena; Jane S Paulsen; Robert K Heaton; Igor Grant
Journal:  Neuropsychology       Date:  2004-10       Impact factor: 3.295

5.  Diabetes, insulin resistance, and dementia among HIV-1-infected patients.

Authors:  Victor G Valcour; Cecilia M Shikuma; Bruce T Shiramizu; Andrew E Williams; Michael R Watters; Pamela W Poff; John S Grove; Ola A Selnes; Ned C Sacktor
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

6.  Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings.

Authors:  Marianna Cherner; Ronald J Ellis; Deborah Lazzaretto; Corinna Young; Monica Rivera Mindt; J Hampton Atkinson; Igor Grant; Robert K Heaton
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

7.  Prevalence of cognitive disorders differs as a function of age in HIV virus infection.

Authors:  James T Becker; Oscar L Lopez; Mary Amanda Dew; Howard J Aizenstein
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

8.  Cognitive functioning in younger and older HIV-1-infected adults.

Authors:  Frances L Wilkie; Karl Goodkin; Imad Khamis; Maria H van Zuilen; Diana Lee; Robert Lecusay; Mauricio Concha; Stephen Symes; Paola Suarez; Carl Eisdorfer
Journal:  J Acquir Immune Defic Syndr       Date:  2003-06-01       Impact factor: 3.731

Review 9.  A systematic review of cognitive decline in the general elderly population.

Authors:  Helen L Park; Janice E O'Connell; Richard G Thomson
Journal:  Int J Geriatr Psychiatry       Date:  2003-12       Impact factor: 3.485

10.  Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort.

Authors:  V Valcour; C Shikuma; B Shiramizu; M Watters; P Poff; O Selnes; P Holck; J Grove; N Sacktor
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

View more
  56 in total

1.  Combined effects of aging and HIV infection on semantic verbal fluency: a view of the cortical hypothesis through the lens of clustering and switching.

Authors:  Jennifer E Iudicello; Steven Paul Woods; Reena Deutsch; Igor Grant
Journal:  J Clin Exp Neuropsychol       Date:  2012-01-31       Impact factor: 2.475

2.  Potential utility of resting-state magnetoencephalography as a biomarker of CNS abnormality in HIV disease.

Authors:  James T Becker; Melissa Fabrizio; Gustavo Sudre; Anna Haridis; Timothy Ambrose; Howard J Aizenstein; William Eddy; Oscar L Lopez; David A Wolk; Lauri Parkkonen; Anto Bagic
Journal:  J Neurosci Methods       Date:  2012-03-05       Impact factor: 2.390

3.  Relationship of ethnicity, age, education, and reading level to speed and executive function among HIV+ and HIV- women: the Women's Interagency HIV Study (WIHS) Neurocognitive Substudy.

Authors:  Jennifer J Manly; Clifford Smith; Howard A Crystal; Jean Richardson; Elizabeth T Golub; Ruth Greenblatt; Esther Robison; Eileen M Martin; Mary Young
Journal:  J Clin Exp Neuropsychol       Date:  2011-08-23       Impact factor: 2.475

4.  Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus.

Authors:  Ned Sacktor; Richard L Skolasky; Christopher Cox; Ola Selnes; James T Becker; Bruce Cohen; Eileen Martin; Eric N Miller
Journal:  J Neurovirol       Date:  2010-10       Impact factor: 2.643

Review 5.  Update on HIV-associated neurocognitive disorders.

Authors:  Tariq B Alfahad; Avindra Nath
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

6.  Extrapyramidal motor signs in older adults with HIV disease: frequency, 1-year course, and associations with activities of daily living and quality of life.

Authors:  Savanna M Tierney; Steven Paul Woods; David Sheppard; Ronald J Ellis
Journal:  J Neurovirol       Date:  2018-12-10       Impact factor: 2.643

Review 7.  Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders.

Authors:  William Tyor; Cari Fritz-French; Avindra Nath
Journal:  J Neurovirol       Date:  2013-10-16       Impact factor: 2.643

8.  Aging and HIV/AIDS: neurocognitive implications for older HIV-positive Latina/o adults.

Authors:  Monica Rivera Mindt; Caitlin Miranda; Alyssa Arentoft; Desiree Byrd; Jennifer Monzones; Armando Fuentes; Francesca Arias; Miguel Arce Rentería; Ana Rosario; Susan Morgello
Journal:  Behav Med       Date:  2014       Impact factor: 3.104

Review 9.  HIV/AIDS in older women: unique challenges, unmet needs.

Authors:  Ramani Durvasula
Journal:  Behav Med       Date:  2014       Impact factor: 3.104

10.  HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon.

Authors:  Georgette D Kanmogne; Callixte T Kuate; Lucette A Cysique; Julius Y Fonsah; Sabine Eta; Roland Doh; Dora M Njamnshi; Emilienne Nchindap; Donald R Franklin; Ronald J Ellis; John A McCutchan; Fidele Binam; Dora Mbanya; Robert K Heaton; Alfred K Njamnshi
Journal:  BMC Neurol       Date:  2010-07-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.